Search News
| 43.40 Delayed Data As of 4:01pm ET |  -0.15 / -0.34%Today’s Change | 37.43 Today|||52-Week Range 50.64 | +0.93% Year-to-Date |
| Should Value Investors Consider Sanofi (SNY) Stock Now? Sep 21 / Zacks.com - Paid Partner Content | Is Artificial Intelligence the Next Big Thing in Biotech? Sep 17 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gil... Sep 20 / Zacks.com - Paid Partner Content | Pharma/Biotech Stocks to Watch This Prostate Cancer Month Sep 14 / Zacks.com - Paid Partner Content |
| Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Sep 19 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Sep 12 / Zacks.com - Paid Partner Content |
| Regeneron Gains on Eylea, Dupixent and Pipeline Progress Sep 18 / Zacks.com - Paid Partner Content | Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA Sep 12 / Zacks.com - Paid Partner Content |
| Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis Sep 17 / Zacks.com - Paid Partner Content |
| Previous close | 43.55 |
| Today’s open | 43.55 |
| Day’s range | 43.20 - 43.60 |
| Volume | 1,226,132 |
| Average volume (3 months) | 2,170,402 |
| Market cap | $109.2B |
| Earnings growth (last year) | -15.68% |
| Earnings growth (this year) | -5.32% |
| Earnings growth (next 5 years) | +6.10% |
| Revenue growth (last year) | +5.92% |
| P/E ratio | 28.5 |
| Price/Sales | 2.76 |
| Price/Book | 1.57 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | -0.74 | -0.70% |
| BMYBristol-Myers Squibb | -0.66 | -1.06% |
| GSKGlaxoSmithKline | -0.10 | -0.25% |
| ABTAbbott Laboratories | +2.39 | +3.46% |
| Next reporting date | November 2, 2018 |
| EPS forecast (this quarter) | $0.97 |
| Annual revenue (last year) | $39.5B |
| Annual profit (last year) | $4.3B |
| Net profit margin | 10.81% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive VP-Finance Jérôme Contamine |
Corporate headquarters Paris, Ile-de-france |
